FDA Opioid Guidance Is Silent On Generics, Cautions That Addicts Can Erase Labeling
This article was originally published in The Pink Sheet Daily
Draft guidance on abuse-deterrent opioids notes that labeling claims may be revised if abusers outwit the abuse-resistant technology; the agency’s evaluation of generic-related citizen petitions continues.
You may also be interested in...
Agency chief counsel says exclusivity for better formulations may need to be considered.
FDA recommends head-to-head studies against already marketed products – an unusual development policy for the agency.
To stimulate new ideas for better formulations, outgoing FDA commissioner Hamburg consulted X Prize Foundation about innovation competition.